Islet Cell and ST2 Axis Dysregulation in Post-Transplant Diabetes Mellitus

Registration

Registration

NCT03415139

Study type

OBSERVATIONAL

Status

UNKNOWN

Enrollment

120

Start

2019-03-12

Primary completion

2023-04

Lead sponsor

Vanderbilt-Ingram Cancer Center

Conditions

Diabetes Mellitus; Cancer

Interventions

DRUG:Oral Glucose Tolerance Test (OGTT); DRUG:2 OGTTs with and without GLP-1 analogue; DRUG:Hyperglycemic clamp procedure

Results posted

FALSE

Registered primary outcomes

• Pre-transplant insulin secretion will be measured as glucose stimulated insulin secretion (GSIS) during a hyperglycemic clamp procedure among patients who do or do not go on to develop PTDM (univariable analysis). [Up to 28 days pre-transplant]
• Pre-transplant insulin secretion will be measured as glucose stimulated insulin secretion (GSIS) during a hyperglycemic clamp procedure among patients who do or do not go on to develop PTDM (multivariable analysis). [Up to 28 days pre-transplant]
• Post-transplant glucagon secretion will be measured during the oral glucose tolerance test among patients who do or do not develop PTDM (univariable analysis). [Up to 100 days after transplant]
• Post-transplant glucagon secretion will be measured during the oral glucose tolerance test among patients who do or do not develop PTDM (multivariable analysis). [Up to 100 days after transplant]
• Plasma IL-33 levels will be measured among patients who do or do not develop PTDM (univariable analysis). [Up to 100 days after transplant]
• Plasma IL-33 levels will be measured among patients who do or do not develop PTDM (multivariable analysis). [Up to 100 days after transplant]